Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results

Jack Chater; Do‐Youn Oh; Masafumi Ikeda; Aiwu Ruth He; Teresa Macarulla; Aaron Dane; J O Park; Farshid Dayyani; G. Wetherill; A. Stell; Barbara Baur; Peng Sun; Arndt Vogel

doi:10.1055/s-0045-1810971

September 1, 2025Zeitschrift für Gastroenterologie

Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results

View at Publisher

Ask AI

Bookmark

Share

Key Points

Safety data indicates that administering durvalumab with gemcitabine through a 30 min infusion is feasible for treatment.
Preliminary results demonstrate effective support for chemotherapy in patients with advanced biliary tract cancer, potentially streamlining care.
Conducted as a Phase 3b single-arm study, the focus was on the safety profile of the new infusion regimen.
These early findings highlight the need for further research to assess long-term outcomes and overall effectiveness.

Implication

Phase 3b TOURMALINE study shows safety of 30 min infusion in advanced biliary tract cancer patients, suggesting improved chemotherapy delivery.

Abstract

Background: The global, single-arm, Phase 3b TOURMALINE study (NCT05771480) assesses the safety and efficacy of D+G-based chemotherapy as first-line tx in aBTC. Optimising care by reducing infusion time may benefit patients and physicians. Preliminary safety data, including 30 min infusion time with D are reported.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chater et al. (2025) studied this question.

synapsesocial.com/papers/68c195559b7b07f3a0618e3f https://doi.org/10.1055/s-0045-1810971

View at Publisher

Ask AI

Bookmark

Share

Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results

Key Points

Implication

Abstract

Discussion

Cite This Study

Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Zeitschrift für Gastroenterologie

Keep reading

More related papers

More from Zeitschrift für Gastroenterologie